NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

32.8M

Vuru Grade

30.66/100

Current Price

$0.64
+0.02 (+3.25%)

Stability Price

$0.62
Fairly valued

Company Metrics

  • 0 P/E
  • 29.59 P/S
  • 5.54 P/B
  • -0.317 EPS
  • -2,345.19% Cash ROIC
  • 3.60 Cash Ratio
  • 0 / 0% Dividend
  • 129,960.00 Avg. Vol.
  • 38.18M Shares
  • 32.8M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Sees Significant Drop in Short Interest (NBY)
Ticker Report - Jan 30, 2015
NovaBay Pharmaceuticals (NYSE:NBY) last released its earnings data on Wednesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01.
NovaBay Pharmaceuticals Inc.: NovaBay Signs Avenova Distribution Agreement ...
The Wall Street Transcript - Jan 26, 2015
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that it has signed a nationwide distribution agreement with ...
NovaBay revamps strategy to focus on Eye Care (NBY)
Seeking Alpha - Jan 7, 2015
NovaBay Pharmaceuticals (NYSEMKT:NBY) refines its business strategy in order to focus on the eye care market. Its initiative consists of three main components: Drive revenue growth by by expanding the sales and marketing organization.
NovaBay Announces New Business Strategy Focusing on Products for Eye Care - Business Wire (press release)
NovaBay Pharma (NBY) Announces Strategic Realignment; May Spin Some non ... - StreetInsider.com (subscription)
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common ...
GlobeNewswire (press release) - Mar 20, 2014
EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an ...
NovaBay off big after trial fails (NBY)
Seeking Alpha (registration) - Aug 20, 2014
The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection ...
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a ...
GlobeNewswire (press release) - Nov 12, 2014
12, 2014 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today reported third quarter 2014 financial ...
NovaBay Pharmaceuticals, Inc. (NBY): NVC-422 Gives NovaBay Huge Growth ...
Seeking Alpha - Dec 9, 2013
NovaBay (NBY) is a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products.
Photo Release -- NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek, Solta ...
GlobeNewswire (press release) - Jan 9, 2014
EMERYVILLE, Calif., Jan. 9 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, has appointed Mark M. Sieczkarek and Dr.
NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of ...
GlobeNewswire (press release) - Dec 2, 2013
EMERYVILLE, Calif., and SHANGHAI, China, Dec. 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products, today announced that it has ...
NovaBay Pharmaceuticals Receives 2 nd Major NeutroPhase Order for 150000 ...
Business Wire (press release) - Oct 27, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner ...